trial

Immuno-Genetic, Inflammation, Retro-Virus, Environment

NCTId NCT02878408
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 1,100 (estimated)
Sponsored by Pr. Marion Leboyer
Primary completion 2028-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
1,100 (estimated)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2014-11-07
Primary completion
2028-11
Eligibility
ALL · 16 Years

Interventions & indications

Drugs
Blood sampling

Sponsors

Pr. Marion LeboyerLead Sponsor
National Research Agency, FranceCollaborator
Assistance Publique - Hôpitaux de ParisCollaborator

Sites

6 total
Créteil, FranceBordeaux, FranceCréteil, FranceParis, FranceParis, FrancePontoise, France

Facts & assertions

4 sourced
Enrollment
1,100
Phase
NA
Primary Completion Date
2028-11
Status
RECRUITING
relationships
The graph out of here
drug
Blood sampling
drug
lead_sponsor
Pr. Marion Leboyer
company
collaborator
National Research Agency, France
company
Assistance Publique - Hôpitaux de Paris
company
indication
Schizophrenia
indication
Bipolar Disorder
indication
Bipolar Disorder
indication